Toxicity to the macula after using small doses cefuroxime for phacoemulsification and vitrectomy combined surgery

Li-Li, Jing; Li, Dongfang; Li, Jun

doi:10.18240/ijo.2022.12.22

Int J Ophthalmol

2022

DOI: 10.18240/ijo.2022.12.22

|View full text |Cite

Toxicity to the macula after using small doses cefuroxime for phacoemulsification and vitrectomy combined surgery

Jing Li-Li¹,

Dongfang Li²,

Jun Li³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime

Jiang,

Zheng,

et al. 2024

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Background: Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear. Objectives: This study aimed to investigate the post-marketing safety of cefuroxime, particularly concerning formulations and routes. Design: A retrospective pharmacovigilance study of cefuroxime was conducted using the data from Food and Drug Administration Adverse Event Reporting System database. Methods: The clinical characteristics and concomitant drugs reported with cefuroxime were investigated. Adverse event signals of cefuroxime were identified based on four disproportionality algorithms. The signal differences of cefuroxime across formulations and routes were further examined. Results: A total of 1810 adverse event reports associated with cefuroxime were identified, and 181 cefuroxime-associated signals were detected. Compared with tablets, injections were more likely to cause preferred terms ‘blood pressure decreased’ and ‘anaphylactic shock’. In addition, system organ class ‘eye disorders’ significantly increased when cefuroxime was administered intraocularly, underscoring the importance of exercising caution regarding ocular toxicity. Conclusion: The adverse events associated with cefuroxime were significantly different across formulations and routes, which deserve special attention in clinical use.

show abstract

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime

Jiang,

Zheng,

et al. 2024

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Toxicity to the macula after using small doses cefuroxime for phacoemulsification and vitrectomy combined surgery

Cited by 1 publication

References 11 publications

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime

Contact Info

Product

Resources

About